Inventor
KOZIAN DETLEF
DE19 patents
⚠️ This page may combine multiple inventors who share the name “KOZIAN DETLEF”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
KOZIAN DETLEF
7 patentsUS8329167B2Dec 11, 2012
EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases
KOZIAN DETLEF0 citations50
US8211427B2Jul 3, 2012
EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases
KOZIAN DETLEF0 citations50
US8114398B2Feb 14, 2012
EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease
KOZIAN DETLEF0 citations50
US8420321B2Apr 16, 2013
Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism
KOZIAN DETLEF0 citations48
US8084198B2Dec 27, 2011
Use of a GIP promoter polymorphism
KOZIAN DETLEF0 citations48
US8198022B2Jun 12, 2012
Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof
KOZIAN DETLEF0 citations47
US8071297B2Dec 6, 2011
Method for the diagnosis and treatment of cardiovascular diseases
KOZIAN DETLEF0 citations42
SANOFI AVENTIS DEUTSCHLAND
6 patentsUS7985562B2Jul 26, 2011
Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism
SANOFI AVENTIS DEUTSCHLAND0 citations50
US7785781B2Aug 31, 2010
Method of diagnosis of a predisposition to develop thrombotic disease and its uses
SANOFI AVENTIS DEUTSCHLAND0 citations50
US7560290B2Jul 14, 2009
Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism
SANOFI AVENTIS DEUTSCHLAND0 citations50
US7892744B2Feb 22, 2011
Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders
SANOFI AVENTIS DEUTSCHLAND0 citations49
US7888020B2Feb 15, 2011
Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof
SANOFI AVENTIS DEUTSCHLAND0 citations48
US7262273B2Aug 28, 2007
Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof
SANOFI AVENTIS DEUTSCHLAND0 citations48
AVENTIS PHARMA GMBH
3 patentsUS6342376B1Jan 29, 2002
Two-color differential display as a method for detecting regulated genes
AVENTIS PHARMA GMBH30 citations87
US6602699B2Aug 5, 2003
Promotor for functional characterization of G-protein coupled receptors in the yeast saccharomyces cerevisiae
AVENTIS PHARMA GMBH6 citations65
US6645741B2Nov 11, 2003
Two-color differential display as a method for detecting regulated genes
AVENTIS PHARMA GMBH0 citations47
SANOFI SA
3 patentsUS9221784B2Dec 29, 2015
Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists
SANOFI SA1 citations51
US9346757B2May 24, 2016
Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
SANOFI SA0 citations41
US9346762B2May 24, 2016
Pyrazole derivatives and their use as LPAR5 antagonists
SANOFI SA0 citations41